168 related articles for article (PubMed ID: 38782182)
21. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
[TBL] [Abstract][Full Text] [Related]
22. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
23. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
[TBL] [Abstract][Full Text] [Related]
24. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Shin S; Kim J; Lee JY; Kim J; Oh CM
J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
[TBL] [Abstract][Full Text] [Related]
25. Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY
Kloock S; Haerting N; Herzog G; Oertel M; Geiger N; Geier A; Sequeira V; Nickel A; Kohlhaas M; Fassnacht M; Dischinger U
Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542814
[TBL] [Abstract][Full Text] [Related]
26. Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom.
Kuchay MS; Isaacs S; Misra A
Diabetes Metab Syndr; 2024 May; 18(5):103034. PubMed ID: 38714040
[TBL] [Abstract][Full Text] [Related]
27. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
28. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy.
Xia M; Varmazyad M; Palacin IP; Gavlock DC; Debiasio R; LaRocca G; Reese C; Florentino R; Faccioli LAP; Brown JA; Vernetti LA; Schurdak ME; Stern AM; Gough A; Behari J; Soto-Gutierrez A; Taylor DL; Miedel M
bioRxiv; 2024 May; ():. PubMed ID: 38712213
[TBL] [Abstract][Full Text] [Related]
30. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
[TBL] [Abstract][Full Text] [Related]
31. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
[TBL] [Abstract][Full Text] [Related]
32. Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges.
Bader H; Yamin S; Alshahwan H; Farraj H; Maghnam J; Abu Omar Y
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892843
[No Abstract] [Full Text] [Related]
33. Liver tissue lipids in metabolic dysfunction-associated steatotic liver disease with diabetes and obesity.
Sourianarayanane A; Brydges CR; McCullough AJ
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(7):102402. PubMed ID: 38909684
[TBL] [Abstract][Full Text] [Related]
34. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
Stefan N; Hartleb M; Popovic B; Varona R
Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
[TBL] [Abstract][Full Text] [Related]
35. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
Metab Syndr Relat Disord; 2024 Jun; ():. PubMed ID: 38868900
[No Abstract] [Full Text] [Related]
36. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD).
Albert SG; Wood EM
J Diabetes Complications; 2024 Jul; 38(7):108777. PubMed ID: 38788522
[TBL] [Abstract][Full Text] [Related]
37. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
Cell Mol Gastroenterol Hepatol; 2024 Apr; 18(2):101348. PubMed ID: 38697356
[TBL] [Abstract][Full Text] [Related]
38. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
[TBL] [Abstract][Full Text] [Related]
39. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
Hachuła M; Kosowski M; Basiak M; Okopień B
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37764998
[TBL] [Abstract][Full Text] [Related]
40. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
